OncoMatch/Clinical Trials/NCT06758037

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

Is NCT06758037 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Drug therapy for dlbcl.

Phase 2RecruitingFirst Affiliated Hospital of Ningbo UniversityNCT06758037Data as of May 2026

Treatment: Drug therapy — To explore the application of HiR (Zebtorizumab, Lenalidomide) + X (targeted drug) guided by NGS molecular typing, the aim is to assess the therapeutic efficacy and safety in newly diagnosed unfit or frail elderly patients with DLBCL aged ≥70 years, and to investigate the genetic subtypes that may benefit from HiR-X.

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Biomarker criteria

Required: MS4A1 overexpression (CD20-positive)

Histologically confirmed CD20-positive diffuse large B-cell lymphoma

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

creatinine < 2 times the upper limit of normal (uln)

Liver function

alt (alanine aminotransferase) / ast (aspartate aminotransferase) < 2.5 x uln; total bilirubin < 2 x uln

Cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify